About the Company
transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TMDX News
TransMedics draws bullish view at Piper Sandler on valuation
TransMedics Group (TMDX) stock gains as Piper Sandler initiated coverage with an Overweight rating and $95 price target, citing attractive valuation. Read more here.
TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Call Transcript February 26, 2024 TransMedics Group, Inc. beats ...
TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating
Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on TransMedics Group (TMDX – Research Report). The associated price ...
TransMedics Group: Huge Opportunity In Organ Transplants
The market is yet to price the huge upside ahead for the company. TransMedics Group, Inc. (NASDAQ:TMDX), a company you probably never heard of, is transforming the organ transplant landscape.
Transmedics Group
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the ...
TransMedics Group Inc TMDX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TransMedics Group Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
TransMedics Group Inc (TMDX)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Loading the latest forecasts...